Intimation of TDS deduction on Interim Dividend for FY 2025-26
This is a standard notification regarding tax implications on dividend payments and does not have a significant impact on the company's operations or stock price.
The announcement is about informing shareholders regarding TDS deduction on interim dividend, which is a routine financial communication.
* Mankind Pharma declared an interim dividend of ₹ 1/- per equity share (100% of nominal value of ₹ 1/- each) for FY 2025-26 on July 31, 2025. * The dividend will be paid to shareholders whose names appear on the Register of Members/depository records as of August 08, 2025 (Record Date). * The dividend will be paid within 30 days of declaration. * The company will deduct tax at source (TDS) at applicable rates as per the Income Tax Act, 1961. * For resident shareholders, TDS will be deducted at 10% if a valid PAN is provided, otherwise at 20%. * No TDS will be deducted for resident individuals if the total dividend during FY 2025-26 does not exceed ₹ 10,000 or if Form 15G/15H is submitted, subject to eligibility. * Non-resident shareholders, including FPIs/FIIs, will have tax withheld as per Sections 195, 196D (1), or 196D (1A) of the Act, plus applicable surcharge and cess. * Non-resident shareholders can avail DTAA benefits by providing necessary documents, including a Tax Residency Certificate (TRC) and Form 10F.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.